Four therapeutics developers completed initial public offerings in the US in October, bringing this year’s total to 28 biopharmaceutical IPOs, but values and returns have slipped for the class of 2016 as biotechnology stocks in general continue their year-to-date slide.
Myovant Sciences Ltd., Ra Pharmaceuticals Inc., CRISPR Therapeutics AG and AzurRx BioPharma Inc. went public in...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
